Advertisement

Efficacy of Risperidone in Managing Maladaptive Behaviors for Children With Autistic Spectrum Disorder: A Meta-Analysis

      Abstract

      Introduction

      Atypical antipsychotic agents are widely used psychopharmacological interventions for autism spectrum disorders (ASDs). Among the atypical antipsychotic agents, risperidone has demonstrated considerable benefits in reducing several behavioral symptoms associated with ASDs. This meta-analysis examined research regarding the effectiveness of risperidone use among children with ASD using articles published since the year 2000.

      Methods

      The database for the analyses comprised 22 studies including 16 open-label and six placebo-controlled studies. Based on the quality, sample size, and study design of studies prior to 2000, the database was then restricted to articles published after the year 2000. Effect sizes were calculated for each reported measure within a study to calculate an average effect size per study.

      Results

      The mean effect size for the database was 1.047 and the sample weighted mean effect size was 1.108, with a variance of 0.18.

      Conclusions

      Outcome measures demonstrated mean improvement in problematic behaviors equaling one standard deviation, and thus current evidence supports the effectiveness of risperidone in managing behavioral problems and symptoms for children with ASD. Although Risperdal has several adverse effects, most are manageable or extremely rare. An exception is rapid weight gain, which is common and can create significant health problems. Overall, for most children with autism and irritable and aggressive behavior, risperidone is an effective psychopharmacological treatment.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Pediatric Health Care
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References
      References marked with an asterisk indicate studies included in the meta-analysis.

        • Aman M.G.
        • Arnold L.E.
        • McDougle C.J.
        • Vitiello B.
        • Scahill L.
        • Davis M.
        • Lindsay R.L.
        • et al.
        Acute and long-term safety and tolerability of risperidone in children with autism.
        Journal of Child and Adolescent Psychopharmacology. 2005; 15: 869-884
        • Aman M.G.
        • Hollway J.
        • McDougle C.
        • Scahill L.
        • Tierney E.
        • McCracken J.T.
        • Posey D.J.
        • et al.
        Cognitive effects of risperidone in children with autism and irritable behavior.
        Journal of Child and Adolescent Psychopharmacology. 2008; 18 (): 227-236
        • American Psychiatric Association
        Diagnostic and statistical manual of mental disorders.
        4th ed. American Psychiatric Association, Washington, DC1994
        • Anderson L.T.
        • Campbell M.
        • Grega D.M.
        • Perry R.
        • Small A.M.
        • Green W.H.
        Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms.
        American Journal of Psychiatry. 1984; 141: 1195-1202
        • Barnard L.
        • Young A.H.
        • Pearson J.
        • Geddes J.
        • O’Brien G.
        A systematic review of the use of atypical antipsychotics in autism.
        Journal of Psychopharmacology. 2002; 16: 93-101
        • Campbell M.
        • Armenteros J.L.
        • Malone R.P.
        • Adams P.B.
        • Eisenberg Z.W.
        • Overall J.E.
        Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study.
        Journal of the American Academic of Child and Adolescent Psychiatry. 1997; 36: 835-843
        • Canitano R.
        Self injurious behavior in autism: Clinical aspects and treatment with risperidone.
        Journal of Neurotransmission. 2006; 113: 425-431
        • Capone G.T.
        • Goyal P.
        • Grados M.
        • Smith B.
        • Kammann H.
        Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: A naturalistic study.
        Journal of Developmental and Behavioral Pediatrics. 2008; 29: 106-116
        • Calarge C.A.
        • Acion L.
        • Kuperman S.
        • Tansey M.
        • Schlechte J.A.
        Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents.
        Journal of Child and Adolescent Psychopharmacology. 2009; 19: 101-109
        • Chavez B.
        • Chavez-Brown M.
        • Sopko M.A.
        • Rey J.A.
        Atypical antipsychotics in children with pervasive developmental disorders.
        Pediatric Drugs. 2007; 9: 249-266
        • Cohen J.
        A power primer.
        Psychological Bulletin. 1992; 112: 155-159
        • Cohen I.L.
        • Campbell M.
        • Posner D.
        • Small A.M.
        • Triebel D.
        • Anderson L.T.
        Behavioral effects of haloperidol in young autistic children: An objective analysis using a within-subjects reversal design.
        Journal of the American Academy of Child and Adolescent Psychiatry. 1980; 19: 665-667
        • Collins F.L.
        One year post-exclusivity adverse event review: Risperidone (Pediatric Advisory Committee Meeting).
        U.S. Food and Drug Administration, Washington, DC2008 November 18
        • Correll C.U.
        Antipsychotic use in children and adolescents.
        Journal of the American Academy of Child & Adolescent Psychiatry. 2008; 47: 9-20
        • Diler R.S.
        • Firat S.
        • Avci A.
        An open label trial of risperidone in children with autism.
        Current Therapeutic Research and Clinical Experience. 2002; 63: 91-102
      1. Elias, M. (2006, May 2). Adult antipsychotics can worsen troubles. USA Today.

        • Elvins R.
        • Green J.
        Pharmacological management of core and comorbid symptoms in autism-spectrum disorder.
        Advances of Psychiatric Treatment. 2010; 16: 349-360
        • Erickson C.A.
        • Stigler K.A.
        • Posey D.J.
        • McDougle C.J.
        Risperidone in pervasive developmental disorders.
        Expert Review of Neurotherapeutics. 2005; 5: 713-719
        • Eugene A.L.
        • Vitiello B.
        • McDougle C.
        • Scahill L.
        • Shah B.
        • Gonzalez N.
        • Tierney E.
        • et al.
        Parent-defined target symptoms respond to risperidone in RUPP Autism Study: Customer approach to clinical trials.
        Journal of the American Academy of Child and Adolescent Psychiatry. 2003; 42: 1443-1450
        • Fleischhaker C.
        • Heiser P.
        • Henninghausen K.
        • Herpertz-Dahlman B.
        • Holtkamp K.
        • Mehler-Wex C.
        • Warnke A.
        • et al.
        Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine, and risperidone.
        Journal of Neural Transmission. 2008; 115: 1599-1608
        • Fombonne E.
        Risperidone improves restricted, repetitive, and stereotyped behaviour in autistic children and adolescents.
        Evidence Based Mental Health. 2006; 9 (6)
        • Gagliano A.
        • Germano E.
        • Pustorino G.
        • Impallomeni C.
        • D’Arrigo C.
        • Calamoneri F.
        • Spina E.
        • et al.
        Risperidone treatment of children with autistic spectrum disorder: Effectiveness, tolerability and pharmacokinetic implications.
        Journal of Child and Adolescent Psychopharmacology. 2004; 14: 39-47
        • Gencer O.F.
        • Neslihan I.E.
        • Miral S.
        • Baykara B.
        • Baykara A.
        • Dirik E.
        Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder.
        European Child and Adolescent Psychiatry. 2008; 17: 217-225
        • Harrison-Woolruch M.
        • Garcia-Quiroga J.
        • Ashton J.
        • Herbison P.
        Safety and usage of atypical medicines in children.
        Drug Safety. 2007; 30: 569-579
        • Heykants J.
        • Huang M.L.
        • Mannens G.
        • Meuldermans W.
        • Snoeck E.
        • Van Beijsterveldt L.
        The pharmaco-kinetics of risperidone in humans: A summary.
        Journal of Clinical Psychiatry. 1994; 55: 13-17
        • Horner R.H.
        • Carr E.G.
        • Strain P.S.
        • Todd A.W.
        • Reed H.K.
        Problem behavior interventions for young children with autism: A research synthesis.
        Journal of Autism and Developmental Disorders. 2002; 32: 423-446
        • Horrigan J.P.
        • Barnhill L.J.
        Risperidone and explosive aggressive autism.
        Journal of Autism and Developmental Disorders. 1997; 27: 313-323
        • James A.C.
        Prescribing antipsychotics for children and adolescents.
        Pediatrics. 2009; 124: 1533-1540
        • Jerrell J.M.
        • McIntyre R.S.
        Adverse events in children and adolescents treated with antipsychotic medications.
        Human Psychopharmacology: Clinical and Experimental. 2008; 23: 283-290
        • Kapur S.
        • Seeman P.
        Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis.
        American Journal of Psychiatry. 2001; 158: 360-369
        • Kuroki T.
        • Nagao N.
        • Nakaha T.
        Neuropharmacology of second-generation antipsychotic drugs: A validity of the serotonin–dopamine hypothesis.
        Progress in Brain Research. 2008; 172: 199-212
        • Kuehn B.M.
        FDA panel OKs 3 antipsychotic drugs for pediatric use, cautions against overuse.
        Journal of the American Medical Association. 2009; 302: 833-834
        • Kwon H.
        Tardive dyskinesia in an autistic patient treated with risperidone.
        American Journal of Psychiatry. 2004; 161: 757-758
        • Lilienfeld S.O.
        Scientifically unsupported and supported interventions for childhood psychopathology: A summary.
        Pediatrics. 2005; 115: 761-764
        • Luby J.
        • Mrakotsky C.
        • Stalets M.M.
        • Belden A.
        • Heffelfinger A.
        • Williams M.
        • Spitznagel E.
        • et al.
        Risperidone in preschool children with autism spectrum disorders: An investigation of safety and efficacy.
        Journal of Child and Adolescent Psychopharmacology. 2006; 16: 575-587
        • Malone R.P.
        Discontinuing risperidone results in relapse in children with autism spectrum disorders.
        Evidence-based Mental Health. 2006; 9: 56-66
        • Malone R.P.
        • Maislin G.
        • Choudhury M.S.
        • Gifford C.
        • Delaney M.A.
        Risperidone treatment in children and adolescents with autism: Short- and long-term safety and effectiveness.
        Journal of the American Academy of Child and Adolescent Psychiatry. 2002; 41: 140-147
        • Mandoki M.W.
        Risperidone treatment of children and adolescents: Increased risk of extrapyramidal side effects?.
        Journal of Child and Adolescent Psychopharmacology. 1995; 5: 49-67
        • Masi G.
        • Cosenza A.
        • Mucci M.
        • Brovedani P.
        Open trial of risperidone in 24 young children with pervasive developmental disorders.
        Journal of the American Academy of Children and Adolescent Psychiatry. 2001; 40: 1206-1214
        • Masi G.
        • Cosenza A.
        • Mucci M.
        • De Vito G.
        Risperidone monotherapy in preschool children with pervasive developmental disorders.
        Journal of Child Neurology. 2001; 16: 395-400
        • Masi G.M.
        • Cosenza A.
        • Mucci M.
        • Brovedani P.
        A 3-year naturalistic study of preschool children with pervasive developmental disorders treated with risperidone.
        Journal of Clinical Psychiatry. 2003; 64: 1039-1047
        • Matson J.L.
        • Dempsey T.
        Autism spectrum disorders: Pharmacotherapy for challenging behaviors.
        Journal of Developmental and Physical Disabilities. 2008; 20: 175-191
        • McCracken J.T.
        • McGough J.
        • Shah B.
        • Cronin P.
        • Hong D.
        • Aman M.G.
        • McMahon D.
        • et al.
        Risperidone in children with autism and serious behavioral problems.
        New England Journal of Medicine. 2002; 347: 314-321
        • McDougle C.J.
        • Scahill L.
        • Aman M.G.
        • McCracken J.T.
        • Tierney E.
        • Davies M.
        • Vitiello B.
        • et al.
        Risperidone for the core symptom domains of autism: Results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology.
        American Journal of Psychiatry. 2005; 162: 1142-1148
        • McNally P.
        • McNichols F.
        • Oslizlok P.
        The QT interval and psychotropic medications in children.
        European Child and Adolescent Psychiatry. 2006; 16 (): 33-47
        • Miral S.
        • Gender O.F.
        • Inal-Emiroglu N.
        • Bayakara B.
        • Bayakara A.
        • Dirik E.
        Risperidone versus haloperidol in children and adolescents with AD.
        European Child and Adolescent Psychiatry. 2008; 17: 1-8
        • Mukaddes N.
        • Abali O.
        • Gurkan K.
        Short-term efficacy and safety of risperidone in young children with autistic disorder (AD).
        World Journal of Biological Psychiatry. 2004; 5: 211-214
        • Nagaraj R.
        • Singhi P.
        • Malhi P.
        Risperidone in children with autism: Randomized, placebo-controlled, double-blind study.
        Journal of Child Neurology. 2006; 21 (): 450-455
        • Owen R.
        • Sikich L.
        • Marcus R.N.
        • Corey-Lisle P.
        • Manos G.
        • McQuade R.D.
        • Findling R.L.
        • et al.
        Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder.
        Pediatrics. 2009; 124 (): 1533-1540
        • Pandina G.J.
        • Bossie C.A.
        • Youssef E.
        • Zhu Y.
        • Dunbar F.
        Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial.
        Journal of Autism and Developmental Disorders. 2007; 37: 367-373
        • Pennington B.F.
        • Ozonoff S.
        Executive functions and developmental psychopathology.
        Journal of Child Psychology and Psychiatry. 1996; 37: 51-87
        • Ratzoni G.
        • Gothelf D.
        • Brand-Gothelf A.
        • Reidman J.
        • Kikinzon L.
        • Gal G.
        • Weizman R.
        • et al.
        Weight gain associated with olanzapine and risperidone in adolescent patients: A comparative prospective study.
        Journal of the American Academic of Child & Adolescent Psychiatry. 2002; 41: 337-343
        • Research Units on Pediatric Psychopharmacology Autism Network
        Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6 months.
        American Journal of Psychiatry. 2005; 162 (): 1361-1369
        • Scahill L.
        • Aman M.G.
        • McDougle C.J.
        • Arnold L.E.
        • McCracken J.T.
        • Handen B.
        • Sukhodolsky D.
        • et al.
        Trial design challenges when combining medication and parent training in children with pervasive developmental disorders.
        Journal of Autism and Developmental Disorders. 2008; 39: 720-729
        • Seeman P.
        Atypical antipsychotics: Mechanism of action.
        Focus. 2004; 2: 48-58
        • Seeman P.
        An update of fast-off dopamine D2 atypical antipsychotics.
        American Journal of Psychiatry. 2005; 162: 1984-1985
        • Shaw S.R.
        • Bruce J.
        • Sharma A.
        • Ouimet T.
        • Glaser S.
        Children with autistic spectrum disorders and atypical anti-psychotic medications: Debate, differences and dual diagnosis.
        Journal of Early Childhood and Infant Psychology. 2009; 5: 37-55
        • Shaw S.R.
        • Dawkins T.
        Atypical antipsychotics and autism.
        in: McCabe P. Shaw S.R. Psychiatric disorders: Current topics and interventions for educators. CA: Sage/Corwin Press, Thousand Oaks2010: 50-59
        • Shea S.
        • Turgay A.
        • Carroll A.
        • Schulz M.
        • Orlik H.
        • Smith I.
        Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
        Pediatrics. 2004; 114: e634-e641
        • Stachnik J.M.
        • Nunn-Thompson C.
        Use of atypical antipsychotics in the treatment of autistic disorder.
        Annals of Pharmacotherapy. 2007; 41: 626-634
        • Troost P.W.
        • Lahuis B.E.
        • Steenhuis M.P.
        • Ketelaars C.E.J.
        • Buitelaar J.K.
        • Engeland H.V.
        • Hoekstra P.J.
        • et al.
        Long-term effects of risperidone in children with autism spectrum disorders: A placebo discontinuation study.
        Journal of the American Academy of Child and Adolescent Psychiatry. 2005; 44: 1137-1144
        • Tyrer P.
        • Kendall T.
        The spurious advance of antipsychotic drug therapy.
        The Lancet. 2009; 373: 4-5
        • Varley C.
        • McClellan J.
        Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents.
        Journal of the American Medical Association. 2009; 302: 1811-1812
        • Weiss M.J.
        • Harris S.L.
        Teaching social skills to people with autism.
        Behavioral Modification. 2001; 25: 785-802
        • West L.
        • Waldrop J.
        Risperidone use in the treatment of behavioural symptoms in children with autism.
        Pediatric Nursing. 2006; 32: 545-549
        • Wetterling T.
        • Mubigbrodt H.E.
        Weight gain: Side effects of atypical neuroleptics?.
        Journal of Clinical Psychopharmacology. 1999; 19: 316-321
        • Williams S.K.
        • Scahill L.
        • Vitiellio B.
        • Aman M.G.
        • Arnold L.E.
        • McDougle C.J.
        • Sparrow S.
        • et al.
        Risperidone and adaptive behavior in children with autism.
        Journal of American Academy of Child and Adolescent Psychiatry. 2006; 45: 431-439
        • Witwer A.
        • Lecavelier L.
        Treatment incidence and patterns in children and adolescents with autism spectrum disorders.
        Journal of Child and Adolescent Psychopharmacology. 2005; 15: 671-681
        • Wonodi I.
        • Reeves G.
        • Carmichael D.
        • Verosky I.
        • Avila M.T.
        • Elliot A.
        • Thaker G.K.
        • et al.
        Tardive dyskinesia in children treated with atypical antipsychotic medications.
        Movement Disorders. 2007; 22: 1777-1782
        • Yan J.
        Risperidone approved to treat schizophrenia in children.
        American Psychiatric News. 2007; 42: 18
        • Zuddas A.
        • Di Martino A.
        • Muglia P.
        • Cianchetti C.
        Long-term risperidone for pervasive developmental disorder: Efficacy, tolerability, and discontinuation.
        Journal of Child and Adolescent Psychopharmacology. 2002; 10: 79-90

      Biography

      Akanksha Sharma, Doctoral Student, Department of Educational and Counselling Psychology, McGill University, Montreal, Quebec, Canada.

      Biography

      Steven R. Shaw, Assistant Professor, Department of Educational and Counselling Psychology, McGill University, Montreal, Quebec, Canada.